Literature DB >> 11368306

Central control of bone formation.

S Takeda1, G Karsenty.   

Abstract

Vertebrates constantly remodel bone to maintain a constant bone mass. Bone remodeling comprises two phases: bone resorption by the osteoclasts followed by bone formation by the osteoblasts. Although the prevailing view about the control of bone remodeling is that it is an autocrine/paracrine phenomenon, the bone resorption arm of bone remodeling is under a tight endocrine control. To date little is known about the regulation of bone formation. We took the observations that gonadal failure favors bone loss and obesity protects from it as an indication that bone mass, body weight, and reproduction could be regulated by the same hormone(s). Leptin is one of these hormones. Leptin inhibits bone formation by the osteoblasts. This function is dominant, and leptin deficiency results in a high bone mass phenotype despite the hypogonadism characterizing these animals. Genetic biochemical and physiological studies demonstrate that leptin inhibits bone formation following its binding to its receptor in the hypothalamus. These results are the first evience that bone remodeling is a hypothalamic process; they imply necessarily that osteoporosis, the most frequent bone remodeling disease, is partly at least a hypothalamic disease. This finding also has therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11368306     DOI: 10.1007/s007740170042

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  20 in total

1.  PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors.

Authors:  Toru Akune; Shinsuke Ohba; Satoru Kamekura; Masayuki Yamaguchi; Ung-Il Chung; Naoto Kubota; Yasuo Terauchi; Yoshifumi Harada; Yoshiaki Azuma; Kozo Nakamura; Takashi Kadowaki; Hiroshi Kawaguchi
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

2.  NMDA receptor subunit composition determines the polarity of leptin-induced synaptic plasticity.

Authors:  Peter R Moult; Jenni Harvey
Journal:  Neuropharmacology       Date:  2011-07-05       Impact factor: 5.250

Review 3.  Neuropeptide Y Y2 receptor in health and disease.

Authors:  S L Parker; A Balasubramaniam
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

4.  Leptin enhances NR2B-mediated N-methyl-D-aspartate responses via a mitogen-activated protein kinase-dependent process in cerebellar granule cells.

Authors:  A J Irving; L Wallace; D Durakoglugil; J Harvey
Journal:  Neuroscience       Date:  2006-01-18       Impact factor: 3.590

5.  Absence of mechanical loading in utero influences bone mass and architecture but not innervation in Myod-Myf5-deficient mice.

Authors:  Cédric Gomez; Valentin David; Nicola M Peet; Laurence Vico; Chantal Chenu; Luc Malaval; Timothy M Skerry
Journal:  J Anat       Date:  2007-03       Impact factor: 2.610

6.  Is leptin a significant predictor of bone mineral density in postmenopausal Turkish women?

Authors:  Serdar Oguz; Omer L Tapisiz; Hakan Aytan; Ilker Gunyeli; Savas Erdem; Gorkem Tuncay; Umit Bilge; Leyla Mollamahmutoglu
Journal:  Rheumatol Int       Date:  2008-09-26       Impact factor: 2.631

Review 7.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

8.  Bone metabolism compensates for the delayed growth in small for gestational age neonates.

Authors:  Roxane Tenta; Ifigeneia Bourgiezi; Evangelos Aliferis; Magdalini Papadopoulou; Antonis Gounaris; Maria Skouroliakou
Journal:  Organogenesis       Date:  2013-01-01       Impact factor: 2.500

9.  Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.

Authors:  Marion David; Irma Machuca-Gayet; Junichi Kikuta; Penelope Ottewell; Fuka Mima; Raphael Leblanc; Edith Bonnelye; Johnny Ribeiro; Ingunn Holen; Rùben Lopez Vales; Pierre Jurdic; Jerold Chun; Philippe Clézardin; Masaru Ishii; Olivier Peyruchaud
Journal:  J Biol Chem       Date:  2014-01-15       Impact factor: 5.157

Review 10.  Spinal cord injury-induced osteoporosis: pathogenesis and emerging therapies.

Authors:  Ricardo A Battaglino; Antonio A Lazzari; Eric Garshick; Leslie R Morse
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.